Cited 0 times in
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 문용화 | - |
dc.contributor.author | 민진식 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-05-19T16:38:16Z | - |
dc.date.available | 2015-05-19T16:38:16Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/106669 | - |
dc.description.abstract | BACKGROUND: This phase III trial was to compare 5-fluorouracil (5-FU), adriamycin, and polyadenylic-polyuridylic acid (poly A:U) against 5-fluorouracil plus adriamycin (FA) for operable gastric cancer. PATIENTS AND METHODS: From 1984 to 1989, patients who had D(2-3) curative resection were randomly assigned to receive chemotherapy or chemoimmunotherapy. Chemotherapy consisted of 12 mg/kg 5-FU every week for 18 months and 40 mg/m2 adriamycin every 3 weeks for 12 cycles. Chemoimmunotherapy consisted of FA plus 100 mg of poly A:U weekly for six cycles and was followed 6 months later by six weekly 50-mg booster injections. RESULTS: A total of 292 patients were enrolled. After excluding 12 ineligible patients, 142 and 138 patients were allocated to each treatment. Patients were balanced with prognostic variables: age, sex, tumor location, differentiation, degree of tumor invasion (T2-T4a), and lymph node status (N0-N2). During the 15-year follow-up, chemoimmunotherapy significantly prolonged overall (P = 0.013) and recurrence-free (P = 0.005) survivals compared with chemotherapy alone. The survival benefits were prominent in the subset of patients with T3/T4a, N2, or stage III. Treatments were generally well tolerated in both arms. CONCLUSIONS: These results indicate a survival advantage of chemoimmunotherapy with a regimen of FA and poly A:U in curatively resected gastric adenocarcinoma. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 520~526 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/secondary | - |
dc.subject.MESH | Adenocarcinoma/surgery* | - |
dc.subject.MESH | Adjuvants, Immunologic/administration & dosage | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Colorectal Neoplasms/secondary | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunotherapy | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoplasm Recurrence, Local/epidemiology | - |
dc.subject.MESH | Neoplasms, Second Primary/epidemiology | - |
dc.subject.MESH | Poly A-U/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/mortality | - |
dc.subject.MESH | Stomach Neoplasms/surgery* | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | H.-C. Jeung | - |
dc.contributor.googleauthor | Y. W. Moon | - |
dc.contributor.googleauthor | S. Y. Rha | - |
dc.contributor.googleauthor | N. C. Yoo | - |
dc.contributor.googleauthor | J. K. Roh | - |
dc.contributor.googleauthor | S. H. Noh | - |
dc.contributor.googleauthor | J. S. Min | - |
dc.contributor.googleauthor | B. S. Kim | - |
dc.contributor.googleauthor | H. C. Chung | - |
dc.identifier.doi | 10.1093/annonc/mdm536 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01370 | - |
dc.contributor.localId | A01411 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.pmid | 18029971 | - |
dc.subject.keyword | adjuvant chemotherapy | - |
dc.subject.keyword | chemoimmunotherapy | - |
dc.subject.keyword | gastric cancer | - |
dc.subject.keyword | poly A:U | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Moon, Yong Wha | - |
dc.contributor.alternativeName | Min, Jin Sik | - |
dc.contributor.alternativeName | Yoo, Nae Choon | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Moon, Yong Wha | - |
dc.contributor.affiliatedAuthor | Min, Jin Sik | - |
dc.contributor.affiliatedAuthor | Yoo, Nae Choon | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 19 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 520 | - |
dc.citation.endPage | 526 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.19(3) : 520-526, 2008 | - |
dc.identifier.rimsid | 46647 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.